Nevertheless, we still do not know about which signaling pathways may be activated or blocked upon IL-2 binding to the IL-2 receptor subunits in RCC, as well as how IL-2-concentration-dependent actions may work in cancer cells. The gene discussed is IL2; the disease is cancer.